Clinical trials: Psoriasis Patients
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Healthy Volunteers, Psoriasis
A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream
This is a Phase 1, randomized, double-blind, vehicle-controlled, SAD / MAD study evaluating three dose levels of PBI-100 topical cream in healthy adult volunteers and/or subjects with psoriasis.
- Trial name
- NCT05514353
- Testing
- PBI-100 Topical Cream, Vehicle Cream
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pyramid Biosciences
Plaque Psoriasis
Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis
The objective of this study is to evaluate the potential of Topicort® (desoximetasone) Topical Spray, 0.25% to suppress hypothalmic pituitary adrenal axis function.
- Trial name
- NCT02340169
- Testing
- Topicort® (desoximetasone) Topical Spray, 0.25%
- Where
- United States
- Volunteers
- 129 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Moderate-to-severe Plaque Psoriasis
A Study of Moderate-to-severe Plaque Psoriasis Patients Response to Secukinumab Treatment in Real-world Setting
This study was a one-arm, retrospective cohort study that observed clinical psoriasis patients who received secukinumab treatment in Indonesia from the 01 August 2017 until the 31 October 2020.
- Trial name
- NCT05787236
- Where
- Indonesia
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis
The purpose of this study is to determine which dose of voclosporin is effective in the treatment of plaque psoriasis compared to placebo.
- Trial name
- SPIRIT (NCT00244842)
- Testing
- voclosporin
- Where
- 31 sites in Canada
- Volunteers
- 451 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Psoriasis
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT03556202
- Testing
- Mirikizumab
- Where
- 229 sites in United States, Argentina and 17 more
- Volunteers
- 1,936 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients
This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.
- Trial name
- ObePso-S (NCT03055494)
- Testing
- Secukinumab
- Where
- 15 sites in United States
- Volunteers
- 102 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea
- Trial name
- POETYK-PSO-3 (NCT04167462)
- Testing
- BMS-986165
- Where
- 34 sites in China, South Korea and 1 more
- Volunteers
- 220 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)
The main aim of the study is to evaluate the efficacy, safety and impact on the health-related quality of life (HRQoL) in participants with moderate-to-severe chronic plaque psoriasis who are treated with tildrakizumab 100…
- Trial name
- TRIBUTE (NCT04229836)
- Testing
- Tildrakizumab 100 mg Solution for Injection
- Where
- 39 sites in Italy, Spain
- Volunteers
- 178 people
- Sponsor
- Almirall, S.A.
Psoriasis Vulgaris
A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis
This is a randomized, double-blind, placebo-controlled, multicentered phase III clinical study to evaluate the efficacy and safety of AK101 in the treatment of subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05120297
- Testing
- AK101
- Where
- 52 sites in China
- Volunteers
- 452 people
- Sponsor
- Akeso
Psoriasis
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects…
- Trial name
- NCT03718299
- Testing
- Injections of tildrakizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Plaque Psoriasis
A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara® in patients with Moderate-to-Severe Plaque Psoriasis.
- Trial name
- VESPUCCI (NCT04595409)
- Testing
- FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab)
- Where
- 16 sites in Estonia, Georgia and 2 more
- Volunteers
- 392 people
- Sponsor
- Bioeq GmbH
Palmoplantar Pustulosis
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT04061252
- Testing
- KHK4827
- Where
- 2 sites in Japan
- Volunteers
- 126 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Plaque Psoriasis
Safety and Efficacy Study of CF101 to Treat Psoriasis
This study will test the hypothesis that CF101, which is under development to treat other immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of chronic plaque psoriasis.
- Trial name
- NCT00428974
- Testing
- CF101 1mg, CF101 2mg, CF101 4mg
- Where
- 4 sites in Israel
- Volunteers
- 76 people
- Sponsor
- Can-Fite BioPharma
Psoriasis
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT04 (Alvotech Biosimilar to Ustekinumab), in patients with moderate to severe plaque psoriasis
- Trial name
- NCT04930042
- Testing
- Stelara, AVT04
- Where
- 30 sites in Estonia, Georgia and 2 more
- Volunteers
- 581 people
- Sponsor
- Alvotech Swiss AG
Psoriasis
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-1 (NCT03624127)
- Testing
- BMS-986165, Apremilast
- Where
- 165 sites in United States, Canada and 9 more
- Volunteers
- 666 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
APremilast After FumaRic Acid Ester Treatment
Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment
- Trial name
- APART (NCT02954081)
- Testing
- Phase I: Fumaric acid esters. Phase II: Apremilast
- Where
- Germany
- Volunteers
- 687 people
- Sponsor
- Amgen
Nail Psoriasis, Plaque Psoriasis
Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis
Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in approximately 34 patients with nail psoriasis for 16 weeks.
- Trial name
- NCT05072886
- Testing
- AT193
- Where
- Australia
- Volunteers
- 34 people
- Sponsor
- Azora Therapeutics Australia Pty Ltd
Plaque Psoriasis
A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.
- Trial name
- CIMREAL (NCT04053881)
- Testing
- Certolizumab pegol
- Where
- 79 sites in Belgium, Canada and 7 more
- Volunteers
- 412 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-2 (NCT03611751)
- Testing
- BMS-986165, Apremilast
- Where
- 205 sites in United States, Australia and 14 more
- Volunteers
- 1,020 people
- Sponsor
- Bristol-Myers Squibb